Cypherpunk Technologies (CYPH) vs Enanta Pharmaceuticals (ENTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cypherpunk Technologies (CYPH) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, losing 38.2% versus a loss of 40.1%. Over five years, ENTA leads with a -91.7% price change compared with -94.4% for CYPH. Enanta Pharmaceuticals is the larger company by market cap ($222.2 million vs $210.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYPH | ENTA |
|---|---|---|
| Share price | $1.41 | $7.62 |
| Market cap | $210.15M | $222.19M |
| 1-day change | -18.02% | -4.51% |
| YTD return | +21.55% | -51.68% |
| 1-year return | -38.16% | -40.14% |
| 5-year return | -94.45% | -91.71% |
| P/E ratio (TTM) | 0.67 | — |
| EPS (TTM) | $2.09 | $-2.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $63.00M |
| Revenue growth (YoY) | — | -3.56% |
| Net income (latest FY) | $4.82M | $-68.25M |
| Operating margin | — | -99.01% |
| Net margin | — | -108.33% |
| 52-week high | $4.19 | $17.15 |
| 52-week low | $0.491 | $7.56 |
| Distance from 52-week high | -66.35% | -55.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +254.61% | +186.48% |
| Average volume | 15.42M | 287.81K |
| Shares outstanding | 149.04M | 29.16M |
| Employees | 6 | 120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cypherpunk Technologies
CYPH stock →Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
CYPH vs ENTA FAQ
Which is bigger, Cypherpunk Technologies or Enanta Pharmaceuticals?
Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $222.19M compared with $210.15M for Cypherpunk Technologies (CYPH).
Which stock has performed better over the past year, CYPH or ENTA?
CYPH returned -38.16% over the past 12 months, compared with -40.14% for ENTA (price return, excluding dividends). Past performance does not predict future results.
Are Cypherpunk Technologies and Enanta Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.